Table 4.
Strength of the correlations between cerebrospinal fluid biomarkers and functional connectivity of regions of interest in patients with aMCI and mild Alzheimer disease
| Group | CSF biomarker | ROI | ROI | r |
|---|---|---|---|---|
| aMCI | Total τ | r1n2 | r8n4 | 0.63 |
| r3n8 | r2n4 | −0.601 | ||
| r3n8 | r8n3 | 0.602 | ||
| r3n8 | r3n4 | 0.637 | ||
| r3n8 | r8n4 | 0.612 | ||
| r8n4 | r5n5 | 0.621 | ||
| Phospho-τ | r6n4 | r3n7 | 0.55 | |
| Aβ1–42 | r3n8 | r2n4 | −0.65 | |
| r4n8 | r8n4 | 0.57 | ||
| Alzheimer disease | Total τ | r3n3 | r2n8 | 0.698 |
| r1n7 | r7n8 | 0.769 | ||
| r2n8 | r4n7 | 0.697 | ||
| r1n6 | r3n7 | 0.765 | ||
| Aβ1–42 | r1n1 | r3n4 | 0.724 | |
| r3n4 | r3n1 | 0.693 | ||
| r1n4 | r5n5 | 0.728 | ||
| Aβ1–42/phospho-τ | r2n5 | r5n5 | 0.693 |
aMCI = amnestic mild cognitive impairment; CSF = cerebrospinal fluid; ROI = region of interest.